The aim of this study was to evaluate the safety, tolerability and efficacy of a topical gel containing histamine dihydrochloride (HDC) versus a placebo gel in preventing oral mucositis in hematopoietic stem cell transplantation (HSCT) patients. A total of 45 patients post-HSCT were enrolled in a prospective longitudinal, placebo-controlled, double-blind study. Patients were evaluated twice weekly for oral mucositis (OMAS, NCI score), oral pain (VAS), oral function and salivary flow rate. Compliance was assessed using a patient diary. Oral mucositis developed in 85% of the HDC group and 63% of the placebo group. The mean maximal intensity for NCI score was 1.4571 in the HDC group and 1.2171.27 in the placebo group (P ¼ 0.37). The mean duration of oral mucositis was 4.773.6 and 2.3372.23 days in the HDC and placebo groups, respectively (P ¼ 0.06). The same trends were measured with OMAS. Visual analogue scale for oral pain and oral function was not significantly different between the two groups. Histamine dihydrochloride was found to be safe. In the search for topical agents for the prevention of mucositis, we found that HDC neither improves nor worsens oral mucositis in HSCT patients. The balance between the pro-and anti-inflammatory effects of HDC should be investigated further in order to acquire a clinically effective topical medication based on its anti-inflammatory properties.
Introduction
Oral mucositis is a common, painful and debilitating toxicity of both cancer chemotherapy and radiation therapy to the head and neck 1 and is a devastating side effect of hematopoietic stem cell transplantation (HSCT). Mucositis manifests as broad areas of mucosal ulceration, often leading to narcotic-dependent discomfort and loss of function 2 and interfering with patient nutrition. 3 Lesions may become infected secondarily. 4 Treatment options are very limited.
According to the pathogenic model of mucositis, 5 the main initiating factor is the presence of reactive oxygen species (ROS), generated during chemotherapy or radiation. Reactive oxygen species damage cells, tissues and blood vessels directly. Following the initiation of oral mucositis by ROS, there is an upregulation and generation of messenger signals. The transcription factor nuclear factor kB (NF-kB) is thought to be a main player; it upregulates proinflammatory cytokines such as TNF-a, IL-6 and IL-2. 5 It is believed that histamine affects these pathways. Histamine potentially attenuates tissue damage by decreasing the generation and release of ROS through H 2 receptors. 6, 7 Histamine can also suppress the release of proinflammatory cytokines from phagocytes. 8 Additionally, the vasodilatory properties of histamine increase blood flow to the affected areas and may improve healing. 9 Taking all these factors into consideration, we hypothesized that therapeutic intervention using histamine in a topical gel may be effective in reducing the duration or severity of oral mucositis.
The primary objectives of this study were to evaluate the safety and tolerability of a gel containing histamine dihydrochloride (HDC) versus a placebo gel in the treatment of oral mucositis induced by pre-HSCT conditioning.
Our secondary objective was to assess the biological activity of an HDC gel in the treatment of oral mucositis induced by pre-HSCT conditioning.
Methods

Patient selection
Patients who were candidates for either allogeneic or autologous HSCT were enrolled in the study. Informed consent was obtained from all patients in accordance with the precepts established by the Helsinki Declaration.
All subjects were at least 18 years of age, male or nonpregnant non-lactating females, with a Karnofsky performance status score of at least 60% and no known hypersensitivity to histamine or any component of the vehicle gel. Adequate dental health was confirmed by the investigators. All patients were expected to remain hospitalized until marrow recovery. Patients with clinically significant acute oral cavity infection defined as any acute viral, bacterial or fungal infection that required specific anti-infective therapy were excluded from the study.
Patients were not allowed to use any investigational agents or H 2 antagonists 30 days before enrollment into the study.
Study medication
A single dose of HDC consisted of 5 ml (one teaspoon) of gel and was applied four times a day. The gel was a semiviscous solution containing 0.12% w/w HDC in a carbomer-based vehicle. The placebo group received the vehicle gel (without HDC). The constituents of the vehicle gel were ethanol, trolamine, carbomer, methyl paraben and propyl paraben. The gel was supplied in a plastic bottle and stored at 41C. Each patient received a kit that contained either the active or placebo gel and plastic measuring teaspoons.
Study design
Randomization. Patients were allocated at random to one of two treatment arms in a blocked randomization schedule. Patient, investigator and staff were blinded to the treatment assignment.
Treatment planning. Patients were evaluated for eligibility during the screening period. Patients were randomized to receive either 0.12% w/w HDC gel or the vehicle control gel. Study drug administration began at the initiation of the conditioning regimen (day 1) and continued to day 28 or at least until day 21 if the patient was NCI 0 (see Efficacy outcome measures).
Compliance. Compliance was assessed based on a diary kept by the nurse for each patient (which remained in the patient's room). Patient compliance level with respect to administration of the study medication was calculated as the ratio between actually applied medication (as determined by the nurse who supplied the dose) and the amount of medication theoretically required to be applied in the interval of treatment. Compliance was also described in terms of duration of use of the study drug.
Concomitant therapy. A standard oral care protocol included rinsing with 10 ml chlorhexidine (CHX) 0.2% mouth-rinse twice daily (Tarodent, Taro Co., Haifa Bay, Israel) and rinsing with up to 3 l of saline per day. Rinsing was not permitted 30 min before or after study drug administration. All patients received amphotericin B (AMB) lozenges 10 mg Â 4/day (Fungilin s , Bristol-Myers Squibb Co., Middlesex, UK). Thirty percent of the patients filled in a compliance diary for the standard oral care protocol. H 2 antagonists were not allowed during the treatment period.
Efficacy outcome measures. Patients receiving at least three doses per day for 5 days were included in the efficacy study.
The primary efficacy end point was assessment of the severity of oral mucositis measured by two scales: NCI CTC v2 Stomatitis and the OMAS scale. The NCI CTC v2 scoring scale for oral mucositis is an assessment tool that evaluates mucositis by function, pain and objective outcomes. 10 The OMAS scale objectively measures the degree of ulceration and erythema in nine distinct anatomic locations in the oral cavity.
11 Both NCI CTC v2 and OMAS scores were obtained twice a week. The primary efficacy variable was the incidence of mucositis.
Evaluation of the severity of oral mucositis was carried out using the maximum and average intensity mucositis score and the duration of mucositis in each group for both scales used. Other end points included mucositis onset day, mucositis peak day, incidence of mucositis of NCI grade 3 and 4 and the incidence of mucositis of OMAS grade 3-5.
The level of oral lubrication was considered a potential confounding factor. Therefore, measurement of unstimulated whole saliva flow rate (sialometry) was conducted twice a week.
Subjective assessments of oral pain and ability to swallow were recorded daily using a 10 cm visual analogue scale (VAS).
Safety outcome measures.
All patients receiving at least one dose of the histamine gel or the vehicle control gel were included in safety analysis.
Safety outcome measures consisted of routine clinical and laboratory evaluations. Vital signs, medical history and physical examination, Karnofsky performance status score and weight were assessed before the study and twice a week during the treatment period. Laboratory evaluations included hematology, chemistry and urinalysis. Blood pressure, pulse and temperature were measured 10, 30 and 60 min after administration of the first dose.
Adverse events. Any untoward medical event observed by the investigator or reported by the subject, regardless of whether it was believed to be treatment related, was considered an adverse event and was reported on the adverse event form. The principal investigator gave his expert opinion as to the likelihood that the adverse event was related to the study drug.
Withdrawal from study. Patients were free to remove themselves from the protocol at any time. Patients were removed from the study in cases of clinically significant adverse events (grade 3 or higher) potentially related to the study medications, excluding adverse events related to HSCT. Patients who missed eight consecutive doses or received less than 14 doses of the study drug in 7 days were removed from the study.
Statistics. All safety parameters were analyzed descriptively. All quantitative measurements and comparisons between the treatment and placebo groups were made using the Mann-Whitney test.
All patients were given the value 0 at the start point. During the analyses of VAS measurements, if a single time point was missing, the average of the preceding and following time point values was calculated and substituted. If two consecutive time points were missing, no substitution was made.
Results
Patients
Between August 2002 and March 2003, 45 patients were screened and enrolled in the study. They were randomized to one of the study arms (21 in the HDC group and 24 in the placebo group). All 45 patients were included in the safety study. Baseline characteristics of patients were comparable between the two groups ( Table 1) .
Thirty-nine patients (20 in the HDC group and 19 in the placebo group) matched the inclusion criteria for the efficacy analysis. Exposure of the subjects to the study medication was comparable ( Table 2) . The difference in average of compliance level (duration and average exposure to the study drug) between the two groups was statistically insignificant (P ¼ 0.35 and P ¼ 0.5) ( Table 2) .
Type of transplant
Twenty-four patients underwent allogeneic HSCT, whereas 21 patients underwent autologous HSCT. The allogeneic HSCT included seven myeloablative transplants, four of which were in the placebo group. The rest of the allogeneic HSCT were non-myeloablative transplants (NST). Most of the NST were in the placebo group (n ¼ 10).
All patients were conditioned pre-HSCT with chemotherapy. When radiotherapy was included in the conditioning regimen, the schedules were 4 and 2 Gy in two patients (in the HDC group) and 7.5 Gy in two patients (in the placebo group). The engraftment day was similar in the two groups; day 21 in the HDC group and day 25 in the placebo group. All patients received anti-viral and anti-pneumocystis carinii pneumonia prophylaxis. Cyclosporine administration, used as graft-versus-host disease (GVHD) prophylaxis in allogeneic HSCT patients, started 4 days before transplantation.
Efficacy
Oral mucositis (all NCI grades) developed in 17 of the 20 patients in the HDC group (85%) and in 12 of the 19 patients in the placebo group (63%). The mean maximal intensity NCI score, the average intensity of NCI and the mean duration of oral mucositis are presented in Table 3 . These parameters were not significantly different between the groups.
The incidence of mucositis NCI grade 3 or 4 was similar in the two groups (Table 3 ) and lasted for no longer than 1 day in either groups.
Oral mucositis developed earlier in the placebo group (mean onset day7s.d. was 11.273 and 9.774 in the HDC group and placebo group, respectively).
Mean mucositis incidences by the OMAS score (all grades) was 75% (15 of 20 patients) in the HDC group and 58% (11 of 19 patients) in the placebo group. Mean maximal intensity by the OMAS score, average intensity by the OMAS score and duration by the OMAS are presented in Table 3 . There were no statistically significant differences between the groups with respect to these parameters.
The mean onset day of oral mucositis (all OMAS grades) was 9.573.5 in the HDC group and 974.1 in the placebo group. The mean peak day of oral mucositis (all OMAS grades) was 11.673.9 in the HDC group and 9.474.4 in the placebo group. 
Sialometry
The trend in both patient groups was for salivary flow rate to decrease throughout the study. There were no significant differences in the mean daily sialometry measurements between the two groups on any day (Table 4 ). There was no temporal correlation between changes in the OMAS score and changes in salivary flow rate (Figure 1 ).
Assessment of oral pain and ability to swallow
Assessment of oral pain and ability to swallow was measured daily using a 10 cm VAS. The mean VAS for pain was 0.8670.89 in the treatment group and 0.5470.80 in the placebo group (P ¼ 0.53). The mean VAS for swallowing was 1.6471.35 in the treatment group and 1.3071.32 in the placebo group (P ¼ 0.74).
Safety
During the first hour after the initial administration of the medication, pulse, blood pressure and temperature were measured three times. All values were within normal limits and the ranges are presented here. 
Adverse events
Patients in the study suffered from a variety of adverse events, all of which were recognized as integral parts of transplantation. Nausea and vomiting often occur in patients undergoing bone marrow transplantation, 12 although there was a clinical impression that the drug increased it. In the HDC group, four patients complained of nausea or vomiting (total of 10 times), whereas in the placebo group only, three patients complained of nausea or vomiting (total of four times). No other systemic or local adverse events were connected with the drug by the investigator.
Compliance with standard oral care protocol A compliance of 46.5715.05% for AMB protocol was recorded in the control group compared to 20.2723.60% in the HDC group. However, this difference was not statistically significant (P ¼ 0.18). In addition, the difference in compliance for the CHX protocol was insignificant between the treatment and placebo groups (mean of 58.99723.87 versus 70.347 24.64%, respectively, P ¼ 0.33). The same trend was noted for saline mouthwash (mean of 16.57718.50 versus 18.91712.15, respectively, P ¼ 0.54).
Discussion
Patients who undergo HSCT often develop mucositis. 5 The incidence and intensity of oral mucositis during HSCT Table 3 Oral mucositis parameters
NCI (all grades)
Maximal intensity (mean7s. depend on the conditioning regimen received. 5 Incidence rates approach 30-50% without total body irradiation. The highest rates are observed in protocols that use total body irradiation, with up to 60% of patients having mucositis generally of higher intensity. 5 Current recommendations for the prevention of oral mucositis include cryotherapy, benzydamine and low-level laser therapy. 13 Many other agents for treatment of oral mucositis have been reported in the literature 13 but there is insufficient evidence to support their use. Recently, keratinocyte growth factor (Palifermin) was reported to reduce the duration and incidence of oral mucositis. However, it was only approved for oral mucositis after intensive chemotherapy and radiotherapy in autologous HSCT. 14 Histamine dihydrochloride was evaluated for the prevention of oral mucositis by means of a double-blind prospective randomized controlled phase II trial. The rationale for prevention of mucositis with HDC is related to its ability to (i) reduce the amount of ROS (ii) suppress proinflammatory cytokines and (iii) increase blood flow, which may facilitate healing. [6] [7] [8] [9] Both study groups included patients scheduled for allogeneic or autologous HSCT, with a diagnosis of hematological and non-hematological malignancies. The study groups were matched regarding age, sex, Karnofsky score, engraftment day and exposure to the study drug.
There was no significant difference between the HDC group and the placebo group with respect to incidence, duration, maximal intensity and average intensity of mucositis. This was validated using two oral mucositis scales -OMAS and NCI. However, these mucositis parameters as well as mucositis onset day and mucositis peak day were worse in the HDC group versus the placebo group.
The sialometry measurements showed a general decrease with time. This is similar to previous reports in the literature. 15 There were no significant differences between the groups with respect to sialometry at any time point during the study.
A correlation between salivary flow rate and mucositis has been reported. 16 In our study, the salivary rate flow decreased with time, with no effect on mucositis scores. We found no association between changes in salivary flow rate and mucositis scores.
Pain is an important aspect of the management of oral mucositis. 17 In this study, there was no difference in pain scores between the two groups. Generally, the mean maximal VAS for pain in both groups was lower than maximal VAS reported in the literature. This reduction may be related to the mucosal coverage by HDC or the vehicle. 18, 19 Histamine dihydrochloride topical gel was found to be safe. No drug-related adverse events were apparent. The drug was well tolerated, although there was a clinical impression that the drug increased the nausea associated with the cytotoxic regimen.
All patients received a standard oral care protocol. The protocol included CHX, saline mouthwashes and AMB lozenges. The standard oral care protocol is used to prevent oral infections during neutropenia. 20, 21 The study design maintained the standard oral care in both groups for ethical reasons. In order to detect unintentional bias, components of the standard oral care regimen were compared. Patient compliance with the standard oral protocol was not significantly different between the two study groups. However, compliance with AMB was lower in the HDC group than in the placebo group. It is possible that the mucositis in the HDC group was intensified by the subclinical presence of Candida. The clinical signs of candidiasis were evaluated twice weekly and were found to be the same in both groups. Histamine is potentially an anti-inflammatory agent, 8, 22 but there are reports suggesting the opposite effect of histamine in the inflammatory process. 23 Histamine contributes to the progression of the inflammatory response by enhancing secretion of proinflammatory cytokines such as IL-6 and synergism with IL-2. 24 This may partly explain the lack of a clinical anti-inflammatory effect.
In this study, HDC in a topical gel was demonstrated to be safe with no severe systemic or local adverse events. As with other drugs, 25 the biologic effect of the drug may be dependent on its dosage. The dosage used in this study was based on an unpublished blinded, placebo-controlled pilot study that was performed in oral mucositis patients secondary to chemotherapy with 5-FU. This unpublished study compared two histamine concentrations and a placebo. It is possible that BMT patients may require different dosages. Therefore, future studies should compare various dosages in BMT patients in order to establish the optimal clinical effect with minimum side effects.
